CardioDx, Inc.

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies.

CardioDx is backed by leaders in life science investing, including Kleiner Perkins Caufield & Byers, TPG Biotech, Mohr Davidow Ventures, Pappas Ventures, Intel Capital, DAG Ventures, Asset Management Company and GE Capital.